Prevalence of SARS-CoV-2 in Patients with Severe Pneumonia in Khuzestan Province, Iran

Farhad Abolnezhadian, Manoochehr Makvandi, Seyed Mohammad Alavi, Azarakhsh Azaran, Shahram Jalilian, Mohammad Rashno, Gholam Abbas Kaydani, Maniya Arshadi, Seyed Mehdi Hosseinizadeh, Hatam Boostani, Seyed Saeed Seyedian, Sasan Moogahi (+11 others)
2020 Iranian Journal of Allergy, Asthma and Immunology  
The emergence of a highly pathogenic virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accounts for severe pneumonia throughout the world. More than 7 million world population have been infected with SARS-CoV-2, and the number of deaths is increasing every day. This study aimed to evaluate the frequency of SARS-CoV-2 in hospitalized patients with acute respiratory infection (ARI). During an outbreak of the SARS-CoV-2, the nasopharyngeal and oropharyngeal swabs were
more » ... l swabs were collected from 909 hospitalized patients with severe pneumonia, including 517 (56.9%) males and 392 (43.1%) females. All the collected samples were from different cities of Khuzestan province from 19 February to- 27 March 2020. The RNA was extracted from samples and subjected to real-time polymerase chain reaction (PCR) tests for the detection of the SARS-CoV-2. Simultaneously, the computerized tomography (CT) scan was tested for the presence of ground-glass opacity in the lung among the patients. Of the total number of 909 specimens, 328 (36.08%) cases, including 185 (20.35%) females and 143 (15.73%) males, were positive for the SARS-CoV-2 while, 581 (63.9%) cases, including 374 (41.14%) males and 207 (22.77%) were negative for the SARS-CoV-2 by real-time PCR (p=0.001).Four hundred sixteen (45.76%) cases were positive for ground-glass opacity in the lung by CT scan, while 328/909 (36.08%) trials proved positive for SARS-CoV-2 by the real-time PCR (p=0.003). In this study, 36.08% of patients were positive for SARS-CoV-2. Although the results of positive cases by CT scan showed higher than real-time PCR, screening the SARS-CoV-2 with a real-time PCR method is the first line of choice.
doi:10.18502/ijaai.v19i5.4462 pmid:33463114 fatcat:l7pmszxum5eedegk4vjmryrd64